600 patients66,869 observations120 daysLIVE

Patient P-01659

Synthetic patientNBL-101 · Day 110 · 75+ · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
82%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 No meaningful changeDietary Support Protocol NP-02
  5. Day 47 Trajectory diverged from predictionObserved response fell below the model's expected path.
  6. Day 58 GI-04 recommendedGI Support Protocol GI-04
  7. Day 59 Patient acceptedStarted GI-04 in the companion
  8. Day 67 GI symptom burden −26% vs expectedGI Support Protocol GI-04
  9. Day 73 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • Toxicity+14
  • Nutritional resilience-11
  • GI instability+7
  • Inflammatory activity+6
  • Treatment adherence-4

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: no meaningful change
  • GI Support Protocol GI-04Day 58
    Result: symptom burden −26%
LIFE OS recommendation
Monitoring Escalation ME-01
90%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
60.1/100
worsening · +6.3 vs previous 14 d
Toxicity
Blood
51.8/100
stable · -1.1 vs previous 14 d
Sleep quality
Wearable
3.7/100
worsening · -1.2 vs previous 14 d
Energy level
Daily log
2.6/10
stable · +0.0 vs previous 14 d
Stress level
Daily log
7.1/10
worsening · +0.5 vs previous 14 d
Steps
Wearable
5,704
worsening · -419 vs previous 14 d
Adherence
Companion
46.1 %
stable · -0.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 30 from the failing basin, 63 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 78%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 78%
  • CR-01 Clinician Review
    100% improved among 8 similar · onset 5 d · confidence 78%
Would not help
  • NP-02 Dietary Support Protocol
    already tried, no meaningful change
  • Keep fat low
    GI +4.2 next day on high-intake days · n 29
  • Keep spicy low
    GI +3.7 next day on high-intake days · n 20
  • Keep histamine low
    GI +3.1 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +4.2detractor · 95%
  • Spicy / capsaicin
    +3.7detractor · 95%
  • Histamine load
    +3.1detractor · 91%
  • Simple carbohydrates
    +2.5detractor · 56%
  • Alcohol
    +0.7no signal · 18%
  • Insoluble fibre
    +0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 60 and rising
    • WearableSleep 5.3 h, below personal baseline
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 38/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 61
    • WearableHRV 17 ms, trending down
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 52
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.1 · butyrate capacity 38/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
24 ms
Sleep
5.6 h
Steps
5,932
Resting HR
68 bpm
Daily log: GI score 60, nutritional resilience 34, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0180421%S19AD-05improved61
P-0168920%S13BR-03no change50
P-0183532%S17CR-01improved56
P-0138831%S17CR-01improved59
P-0169630%S20CR-01improved59
P-0170830%S07CR-01improved59
P-0137129%S06CR-01improved63
P-0144229%S13CR-01improved61
P-0187728%S01CR-01improved67
P-0143021%S05CR-01improved54
P-0134220%S11DT-01improved48
P-0176720%S14DT-01no change63